Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Modern smartphones have the chops to handle diabetes monitoring and management, making them a potentially alluring platform from which to build an artificial pancreas.
The FDA says Nova Biomedical’s glucose test strip recall is a Class I risk, representing the most significant potential danger to patients.
A federal jury hits C.R. Bard with a $2 million judgment after finding its Avaulta pelvic mesh defective, ruling that Bard failed to warn about problems with the product.